 Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 6 | 7 | | 1996 | 1 | 2 | 3 | | 1997 | 2 | 7 | 9 | | 1998 | 0 | 5 | 5 | | 1999 | 4 | 5 | 9 | | 2000 | 3 | 7 | 10 | | 2001 | 2 | 5 | 7 | | 2002 | 3 | 4 | 7 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 5 | 6 | | 2005 | 4 | 9 | 13 | | 2006 | 3 | 11 | 14 | | 2007 | 7 | 4 | 11 | | 2008 | 9 | 4 | 13 | | 2009 | 11 | 14 | 25 | | 2010 | 13 | 14 | 27 | | 2011 | 12 | 11 | 23 | | 2012 | 13 | 6 | 19 | | 2013 | 14 | 16 | 30 | | 2014 | 32 | 5 | 37 | | 2015 | 13 | 11 | 24 | | 2016 | 14 | 11 | 25 | | 2017 | 25 | 12 | 37 | | 2018 | 23 | 9 | 32 | | 2019 | 32 | 14 | 46 | | 2020 | 22 | 35 | 57 | | 2021 | 18 | 37 | 55 | | 2022 | 6 | 41 | 47 | | 2023 | 0 | 56 | 56 | | 2024 | 21 | 24 | 45 | | 2025 | 32 | 5 | 37 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Polites SF, Aldrink JH, Lautz TB, Vierkant RA, Ragan MV, Reiter A, Chen SY, Kim ES, Rinehardt HN, Malek MM, Fleming AM, Murphy AJ, Roach JP, Radhakrishnan S, Kastenberg ZJ, Piche N, Osman Y, Iii HNL, Tracy ET, Favela J, Le HD, Marquart J, Craig B, Lal DR, Seemann N, Petroze R, Rich BS, Glick RD, Selesner L, Yoo A, Fialkowski E, Brown EG, Boehmer C, Dasgupta R, Langham MR. Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection. Pediatr Blood Cancer. 2025 Dec; 72(12):e32029.
-
Robin TP, Hu J, Jones BL, Patton T, Diamond JR, Behbakht K, Lefkowits C, Corr BR, Fisher CM. Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer. Gynecol Oncol. 2025 Sep; 200:175-179.
-
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. Cancer Cell. 2025 Aug 11; 43(8):1568-1586.e10.
-
Groisser A, Frantz A, Geller JI, Ortiz MV, Walterhouse D, Ranalli M, Woods-Swafford W, Schoettler P, Garrington T, Mullen EA, Ash S, Bardhan P, Balis F, Dome JS. Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor. Pediatr Blood Cancer. 2025 Oct; 72(10):e31915.
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
-
Vicini F, Shah C, Mittal K, Weinmann S, Leo M, Mann GB, Warnberg F, Rabinovitch R, Czerniecki B, Meattini I, Khan AJ, Jhawar S, Gerber N, Willey SC, Borgen P, AlHilli Z, Kruse M, Dabbs D, Shivers SC, Daily A, Whitworth P, Alvarado M, Mouabbi JA, Moran M, Rugo H, O'Shaughnessy JA, Bremer T. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates. Int J Radiat Oncol Biol Phys. 2025 Nov 15; 123(4):1090-1101.
-
Sterner J, Andersson M, Olofsson A, Jansson H, Strömberg C, D'Souza M, Sturesson C, Sparrelid E, Gerling M, Gilg S, Engstrand J. Impact of post-hepatectomy liver failure on recurrence following major hepatectomy for colorectal cancer liver metastases. HPB (Oxford). 2025 Oct; 27(10):1309-1317.
-
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025 Aug 20; 43(24):2671-2678.
-
Akabane M, Kawashima J, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. International validation of a natural-killer-cell-based model to predict recurrence-free survival in hepatocellular carcinoma. HPB (Oxford). 2025 Oct; 27(10):1259-1269.
-
Kawashima J, Endo Y, Khalil M, Woldesenbet S, Akabane M, Ruzzenente A, Ratti F, Marques H, Oliveira S, Balaia J, Cauchy F, Lam V, Poultsides G, Kitago M, Popescu I, Martel G, Gleisner A, Hugh TJ, Aldrighetti L, Endo I, Pawlik TM. Development and validation of a preoperative risk prediction model for severe complications and very early recurrence after liver resection for hepatocellular carcinoma. Surgery. 2025 Sep; 185:109527.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|